Dallas, Texas.
Makawao, Hawaii.
Ophthalmol Glaucoma. 2020 Jan-Feb;3(1):1-6. doi: 10.1016/j.ogla.2019.12.003.
In 2018, the American Glaucoma Society (AGS), the world’s largest professional society of glaucoma subspecialists, convened a 12-member task force of experts to craft a position statement about microinvasive glaucoma surgery (MIGS). The main objective of this position statement is to provide a succinct overview of these procedures and to address some misconceptions about MIGS. The members of the task force were selected by the AGS Board of Directors and include AGS members with expertise in developing MIGS, teaching MIGS, performing research on use and outcomes of these procedures, and working with the United States Food and Drug Administration (FDA) and other regulatory agencies about developing criteria to evaluate the efficacy and safety of these devices. Each of the sections of the position statement was prepared by subgroups of the task force, and then the material from the various sections was aggregated, and the leader of the task force (J.D.S.) merged the material into a cohesive draft. This draft was shared with the AGS Executive Committee and other members of the AGS Board of Directors for additional input.
2018 年,世界上最大的青光眼专科医生专业协会——美国青光眼学会(AGS)召集了一个由 12 名专家组成的特别工作组,专门制定了一份关于微创青光眼手术(MIGS)的立场声明。这份立场声明的主要目的是简要概述这些手术,并解决有关 MIGS 的一些误解。特别工作组的成员由 AGS 董事会选定,其中包括在开发 MIGS、教授 MIGS、研究这些手术的使用和结果以及与美国食品和药物管理局(FDA)和其他监管机构合作制定评估这些设备疗效和安全性的标准方面具有专业知识的 AGS 成员。立场声明的每一节都由工作组的分组准备,然后从各个部分汇总材料,工作组的负责人(J.D.S.)将材料合并成一个有凝聚力的草案。该草案与 AGS 执行委员会和 AGS 董事会的其他成员共享,以获取更多意见。